Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: New prognostic factors for malignant well-differentiated endocrine tumors

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 963-970

  Asnacios, Amani ^a   Courbon, Frédéric ^a   Rochaix, Philippe ^a   Bauvin, Eric ^a   Cances Lauwers, Valérie ^a   Susini, Christiane ^a   Schulz, Stefan ^a   Boneu, Andrée ^a   Guimbaud, Rosine ^a   Buscail, Louis ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; PENTETREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENDOCRINE TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCINTIGRAPHY; TUMOR LOCALIZATION; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; ENDOCRINE GLAND NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 39749102502     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.7431     Document Type: Article

References (34)

1. Lamberts SWJ, Krenning EP, Reubi J-C: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-482, 1991
2. Krenning EP, Kwekkeboom DJ, Bakker WH, et al: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731, 1993
3. Modlin IM, Latich I, Zikusoka M, et al: Gastrointestinal carcinoids: The evolution of diagnostic strategies. J Clin Gastroenterol 40:572-582, 2006
4. Jensen RT, Niederle B, Mitry E, et al: Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84:173-182, 2006
5. Termanini B, Gibril F, Reynolds JC: Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112:335-347, 1997
6. Plockinger U, Wiedenmann B: Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendocrinology 80:35-38, 2004 (suppl 1)
7. Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966-973, 2004
8. Susini C, Buscail L: Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733-1742, 2006
9. Ducreux M, Ruszniewski P, Chayvialle JA, et al: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95:3276-3281, 2000
10. Schilling FH, Ambros PF, Bihl H, et al: Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas. Med Pediatr Oncol 36:56-60, 2001
11. Orlando C, Raggi CC, Bagnoni L, et al: Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium-111- pentetreotide. Med Pediatr Oncol 36:224-226, 2001
12. Hoyer D, Bell G-I, Berelowitz M, et al: Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16:86-88, 1995
13. Buscail L, Estève JP, Saint-Laurent N, et al: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92:1580-1584, 1995
14. Papotti M, Bongiovanni M, Volante M, et al: Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461-475, 2002
15. Kulaksiz H, Eissele R, Rossler D, et al: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50:52-60, 2002
16. Mundschenk J, Unger N, Schulz S, et al: Somatostatin receptor subtypes in human pheochromocytoma: Subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 88:5150-5157, 2003
17. Fjallskog ML, Ludvigsen E, Stridsberg M, et al: Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 20:59-67, 2003
18. Solcia E, Klöppel G, Sobin LH: Histological typing of endocrine tumors, in: WHO International Histological Classification of Tumors (ed 2). Berlin, Germany, Springer-Verlag, 2000, pp 61-68
19. Falconi M, Plockinger U, Kwekkeboom DJ, et al: Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 84:196-211, 2006
20. La Rosa S, Sessa F, Capella C, et al: Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429:323-333, 1996
21. Lloyd RV: Utility of Ki-67 as a prognostic marker in pancreatic endocrine neoplasms. Am J Clin Pathol 109:245-247, 1998
22. Madeira I, Terris B, Voss M, et al: Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43:422-427, 1998
23. Janson ET, Holmberg L, Stridsberg M, et al: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral centre. Ann Oncol 8:685-690, 1997
24. Plöckinger U, Rindi G, Arnold R, et al: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours: A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394-424, 2004
25. 111In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30:BP140-BP147, 2003
26. Vezzosi D, Bennet A, Rochaix P, et al: Octreotide in insulinoma patients: Efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 152:757-767, 2005
27. Cordelier P, Esteve JP, Najib S, et al: Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation. J Biol Chem 281:19156-19171, 2006
28. Reubi JC, Schär JC, Waser B, el al: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273-282, 2000
29. 111In-DTPA-D-Phe1] octreotide in somatostatin receptor-positive organs. J Nucl Med 44:1315-1321, 2003
30. Janson ET, Gobl A, Kalkner KM, et al: A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56:2561-2565, 1996
31. Buscail L, Saint-Laurent N, Chastre E, et al: Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56:1823-1827, 1996
32. Delesque N, Buscail L, Estève J-P, et al: Sst2 somatostatin receptor expression reverses the tumorigenicity of human pancreatic cancer cells. Cancer Res 57:956-962, 1997
33. Rochaix P, Delesque N, Estève J-P, et al: Gene therapy for pancreatic carcinoma: Local and distant antitumor bystander effect after somatostatin receptor sst2 gene transfer. Hum Gene Ther 10:995-1008, 1999
34. Carrère N, Vernejoul F, Souque A, et al: Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther 16:1175-1193, 2005